Juno Therapeutics Prices $250 Million Follow-on Offering
September 21 2017 - 9:13PM
Business Wire
Juno Therapeutics, Inc. (NASDAQ:JUNO), a biopharmaceutical
company developing innovative cellular immunotherapies for the
treatment of cancer, today announced the pricing of its follow-on
public offering of 6,100,000 shares of its common stock at a price
to the public of $41.00 per share. In addition, Juno has granted
the underwriters a 30-day option to purchase up to an additional
915,000 shares of common stock. Juno intends to use the net
proceeds of the offering for general corporate purposes and working
capital.
The offering is expected to close on September 26, 2017, subject
to customary closing conditions. Concurrent with the completion of
the follow-on public offering, Juno will complete a private
placement of 659,415 shares of its common stock, at a price of
$41.00 per share, to a subsidiary of Celgene Corporation. Aggregate
gross proceeds from the follow-on public offering and concurrent
private placement, before deducting underwriting discounts and
commissions, in the case of the follow-on public offering, and
expenses payable by Juno will be $277.1 million (or approximately
$318.7 million if the underwriters exercise their option to
purchase additional shares in full).
Morgan Stanley and J.P. Morgan are acting as joint book-running
managers for the offering. Barclays and Leerink Partners are acting
as co-lead managers and Wells Fargo Securities, Raymond James and
Wedbush PacGrow are acting as co-managers.
A registration statement on Form S-3 relating to the common
stock offered in the public offering described above was filed with
the Securities and Exchange Commission (SEC) on September 20, 2017
and was automatically effective upon filing. The offering is being
made only by means of a written prospectus that forms a part of the
registration statement. Copies of the final prospectus related to
the offering may be obtained from Morgan Stanley & Co. LLC,
Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New
York, NY 10014 and J.P. Morgan Securities LLC, c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, New York
11717, Attn: Prospectus Department, or by telephone at (866)
803-9204.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the securities being offered, nor
shall there be any sale of the securities being offered in any
state or other jurisdiction in which such offer, solicitation or
sale would be unlawful prior to the registration or qualification
under the securities laws of any such state or other
jurisdiction.
About Juno Therapeutics
Juno Therapeutics is building a fully integrated
biopharmaceutical company focused on developing innovative cellular
immunotherapies for the treatment of cancer. Founded on the vision
that the use of human cells as therapeutic entities will drive one
of the next important phases in medicine, Juno is developing
cell-based cancer immunotherapies based on chimeric antigen
receptor and high-affinity T cell receptor technologies to
genetically engineer T cells to recognize and kill cancer. Juno is
developing multiple cell-based product candidates to treat a
variety of B-cell malignancies as well as multiple solid tumors and
multiple myeloma. Several product candidates have shown compelling
clinical responses in clinical trials in refractory leukemia and
lymphoma conducted to date. Juno's long-term aim is to leverage its
cell-based platform to develop new product candidates that address
a broader range of cancers and human diseases. Juno brings together
innovative technologies from some of the world's leading research
institutions, including the Fred Hutchinson Cancer Research
Center, Memorial Sloan Kettering Cancer Center, Seattle
Children's Research Institute (SCRI), the University
of California, San Francisco, and The National
Cancer Institute. Juno Therapeutics has an exclusive
license to the St. Jude Children’s Research Hospital patented
technology for CD19-directed product candidates that use 4-1BB,
which was developed by Dario Campana, Chihaya Imai, and
St. Jude Children’s Research Hospital. Juno’s product
candidate JCAR017 was developed in collaboration with SCRI and
others.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170921006239/en/
Juno TherapeuticsInvestor Relations:Nicole Keith,
206-566-5521nikki.keith@junotherapeutics.comorMedia:Christopher
Williams, 206-566-5660chris.williams@junotherapeutics.com
JUNO THERAPEUTICS, INC. (NASDAQ:JUNO)
Historical Stock Chart
From Mar 2024 to Apr 2024
JUNO THERAPEUTICS, INC. (NASDAQ:JUNO)
Historical Stock Chart
From Apr 2023 to Apr 2024